The Method of Minimal Residual Disease Detection With Circulating Tumor DNA and Its Clinical Applications in Colorectal Cancer

Overview

Journal Cancer Rep (Hoboken)

Specialty Oncology

Date 2025 Mar 4

PMID 40033897

Authors

Ming Liu

Tianhao Mu

Jia Gu

Mingyan Xu

Shifu Chen

Affiliations

Soon will be listed here.

Abstract

Background: Colorectal cancer (CRC) remains a significant health concern in the world. The existing standard of care guidelines for CRC surveillance fall short of effectively and timely detecting recurrence or metastasis.

Recent Findings: In recent years, circulating tumor DNA (ctDNA) has emerged as a promising material for minimal residual disease (MRD) detection. In this article, we provide an exhaustive review of the methods utilized for MRD detection via ctDNA, present evidence supporting the potential of ctDNA MRD as a valuable biomarker in clinical applications, and engage in a discussion regarding ongoing ctDNA MRD-based clinical trials in CRC. Finally, we offer insights into future prospects of ctDNA-based MRD methodological advancements and clinical research.

Conclusion: It is foreseeable that more sensitive, flexible, and economical MRD detection methods will emerge with the deeper research on cell-free DNA (cfDNA) genomics, fragmentomics, methylomes, and nucleosome imprinting. At the same time, MRD-guided intervention studies will evolve for revolutionizing the treatment paradigm of CRC.

References

Larribere L, Martens U . Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors. Cancers (Basel). 2021; 13(22). PMC: 8616165. DOI: 10.3390/cancers13225698. View

Loupakis F, Sharma S, Derouazi M, Murgioni S, Biason P, Rizzato M . Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. JCO Precis Oncol. 2021; 5. PMC: 8315303. DOI: 10.1200/PO.21.00101. View

Zviran A, Schulman R, Shah M, Hill S, Deochand S, Khamnei C . Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020; 26(7):1114-1124. PMC: 8108131. DOI: 10.1038/s41591-020-0915-3. View

Hu Y, Ulrich B, Supplee J, Kuang Y, Lizotte P, Feeney N . False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin Cancer Res. 2018; 24(18):4437-4443. DOI: 10.1158/1078-0432.CCR-18-0143. View

Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H . Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023; 29(1):127-134. PMC: 9873552. DOI: 10.1038/s41591-022-02115-4. View

Chakravarty D, Solit D . Clinical cancer genomic profiling. Nat Rev Genet. 2021; 22(8):483-501. DOI: 10.1038/s41576-021-00338-8. View

Lo Y, Han D, Jiang P, Chiu R . Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science. 2021; 372(6538). DOI: 10.1126/science.aaw3616. View

Abbosh C, Birkbak N, Wilson G, Jamal-Hanjani M, Constantin T, Salari R . Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017; 545(7655):446-451. PMC: 5812436. DOI: 10.1038/nature22364. View

Hardiman K, Felder S, Friedman G, Migaly J, Paquette I, Feingold D . The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surveillance and Survivorship Care of Patients After Curative Treatment of Colon and Rectal Cancer. Dis Colon Rectum. 2021; 64(5):517-533. DOI: 10.1097/DCR.0000000000001984. View

10.

Zhou J, Wang C, Lin G, Xiao Y, Jia W, Xiao G . Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study. Clin Cancer Res. 2020; 27(1):301-310. DOI: 10.1158/1078-0432.CCR-20-2299. View

11.

Razavi P, Li B, Brown D, Jung B, Hubbell E, Shen R . High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019; 25(12):1928-1937. PMC: 7061455. DOI: 10.1038/s41591-019-0652-7. View

12.

Cai G, Cai M, Feng Z, Liu R, Liang L, Zhou P . A Multilocus Blood-Based Assay Targeting Circulating Tumor DNA Methylation Enables Early Detection and Early Relapse Prediction of Colorectal Cancer. Gastroenterology. 2021; 161(6):2053-2056.e2. DOI: 10.1053/j.gastro.2021.08.054. View

13.

Shaukat A, Levin T . Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol. 2022; 19(8):521-531. PMC: 9063618. DOI: 10.1038/s41575-022-00612-y. View

14.

Kou R, Lam H, Duan H, Ye L, Jongkam N, Chen W . Benefits and Challenges with Applying Unique Molecular Identifiers in Next Generation Sequencing to Detect Low Frequency Mutations. PLoS One. 2016; 11(1):e0146638. PMC: 4709065. DOI: 10.1371/journal.pone.0146638. View

15.

Zhu M, Taylor W, Mahoney D, Then S, Berger C, Burger K . Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies. Cancers (Basel). 2023; 15(24). PMC: 10742045. DOI: 10.3390/cancers15245778. View

16.

Liu W, Li Y, Tang Y, Song Q, Wang J, Li N . Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA. EBioMedicine. 2022; 78:103945. PMC: 8933829. DOI: 10.1016/j.ebiom.2022.103945. View

17.

Werner T, Kock S, Weber I, Kayser G, Werner M, Lassmann S . Validation of a DNA-Based Next-Generation Sequencing Test for Molecular Diagnostic Variant and Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tissue Specimens and Liquid Biopsy Plasma/Cell-Free DNA Samples. J Mol Diagn. 2022; 24(7):784-802. DOI: 10.1016/j.jmoldx.2022.04.001. View

18.

Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag C, Laversanne M . Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023; 72(2):338-344. DOI: 10.1136/gutjnl-2022-327736. View

19.

Alix-Panabieres C, Pantel K . Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021; 11(4):858-873. DOI: 10.1158/2159-8290.CD-20-1311. View

20.

Parikh A, Van Seventer E, Siravegna G, Hartwig A, Jaimovich A, He Y . Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021; 27(20):5586-5594. PMC: 8530842. DOI: 10.1158/1078-0432.CCR-21-0410. View